Universty of Michigan
Welcome,         Profile    Billing    Logout  
 4 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Belloli, Elizabeth
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Recruiting
3
576
Canada, US
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
PRECISIONS, NCT04300920: Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection () Trial

Active, not recruiting
3
202
US
N-acetyl cysteine, NAC, Placebo
Weill Medical College of Cornell University, University of Virginia, University of Michigan, Pulmonary Fibrosis Foundation, University of Washington, National Heart, Lung, and Blood Institute (NHLBI), Three Lakes Foundation
Idiopathic Pulmonary Fibrosis
02/26
02/26
NCT06265532: Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect

Recruiting
1
22
US
EGCG 300 mg, Dietary Supplement: EGCG Capsules with EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks., Placebo for EGCG 300 mg, Dietary Supplement: Placebo Placebo (2 capsules) taken orally daily for 12 weeks., EGCG 600 mg, Dietary Supplement: EGCG Capsules with EGCG (at least 94% purity). 600 mg EGCG (4 capsules) taken orally daily for 12 weeks., Placebo for EGCG 600 mg, Dietary Supplement: Placebo Placebo (4 capsules) taken orally daily for 12 weeks.
Hal Chapman, Cornell University, Massachusetts General Hospital, University of Michigan, National Heart, Lung, and Blood Institute (NHLBI)
Idiopathic Pulmonary Fibrosis
03/26
03/26
NCT05195918: Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

Recruiting
1
50
US
EGCG 300 mg + Nintedanib, epigallocatechin-3-gallate + Ofev, EGCG 300 mg + Pirfenidone, epigallocatechin-3-gallate + Esbriet, Placebo 2 capsules + Nintedanib or Pirfenidone, Placebo + Ofev or Esbriet, EGCG 600 mg + Nintedanib, EGCG 600 mg + Pirfenidone, Placebo 4 capsules + Nintedanib or Pirfenidone
Hal Chapman, University of Michigan, Cornell University, Massachusetts General Hospital, Temple University, University of Washington, University of Virginia
Idiopathic Pulmonary Fibrosis
04/26
04/26
PHINDER, NCT05776225: Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection

Recruiting
N/A
200
US
Right heart catheterization (RHC)
United Therapeutics
Interstitial Lung Disease, Pulmonary Hypertension
05/25
06/25

Download Options